MedTrace Logo

Hydroxychloroquine for the First Thrombosis Prevention in Antiphospholipid Antibody Positive Patients

NCT01784523 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2021-09-14

Study results available
· View outcomes & findings →

Summary

In this multi-center international study, our aim is to determine the effectiveness of HCQ for primary thrombosis prophylaxis in persistently aPL-positive but thrombosis-free patients without systemic autoimmune diseases.

Conditions

  • Antiphospholipid Syndrome

Interventions

DRUG

Hydroxychloroquine

Sponsors & Collaborators

  • AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking

    collaborator UNKNOWN

  • The New York Community Trust

    collaborator OTHER

  • Hospital for Special Surgery, New York

    lead OTHER

Principal Investigators

  • Doruk Erkan, MD · Hospital for Special Surgery, New York

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01784523 on ClinicalTrials.gov